CAI:RMDA (Egypt)
Â
Ordinary Shares
E£
5.1
+0.090 (+1.8%)
Jul 6
Business Description
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents
ISIN : EGS381B1C015
Share Class Description:
CAI:RMDA: Ordinary SharesCompare
Compare
Traded in other countries / regions
RMDA.Egypt IPO Date
2019-11-27Description
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. The company is engaged in the Manufacturing, marketing, selling and storing of pharmaceutical reagents for human and veterinary use; manufacturing, marketing, selling and storing of diagnostic reagents necessary for individuals, laboratories and hospitals; importing pharmaceutical reagents and raw materials necessary for serving the its purposes without trading; producing pharmaceutical reagents for human and veterinary and diagnostic use for others and by others; and producing food supplements for human use for others and by others. It has two segments: production and selling of pharmaceutical products, which generates maximum revenue; and manufacturing for others (Toll manufacturing).
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.02 | |||||
Equity-to-Asset | 0.42 | |||||
Debt-to-Equity | 1.01 | |||||
Debt-to-EBITDA | 2.08 | |||||
Interest Coverage | 2.02 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 3.81 | |||||
Beneish M-Score | -1.76 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 38.9 | |||||
3-Year EBITDA Growth Rate | 28.2 | |||||
3-Year EPS without NRI Growth Rate | 13.4 | |||||
3-Year FCF Growth Rate | -97.9 | |||||
3-Year Book Growth Rate | 11.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 51.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 15.24 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 56.03 | |||||
9-Day RSI | 49.56 | |||||
14-Day RSI | 50.04 | |||||
3-1 Month Momentum % | 20.57 | |||||
6-1 Month Momentum % | 54.55 | |||||
12-1 Month Momentum % | 52.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.17 | |||||
Quick Ratio | 0.88 | |||||
Cash Ratio | 0.02 | |||||
Days Inventory | 187.97 | |||||
Days Sales Outstanding | 78.73 | |||||
Days Payable | 54.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.6 | |||||
Dividend Payout Ratio | 0.41 | |||||
3-Year Dividend Growth Rate | 152 | |||||
Forward Dividend Yield % | 0.6 | |||||
5-Year Yield-on-Cost % | 0.6 | |||||
3-Year Average Share Buyback Ratio | -0.7 | |||||
Shareholder Yield % | -8.14 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 49 | |||||
Operating Margin % | 24.91 | |||||
Net Margin % | 7.42 | |||||
EBITDA Margin % | 24.97 | |||||
FCF Margin % | -19.1 | |||||
OCF Margin % | -1.58 | |||||
ROE % | 14.97 | |||||
ROA % | 6.3 | |||||
ROIC % | 17.69 | |||||
3-Year ROIIC % | 19.69 | |||||
ROC (Joel Greenblatt) % | 42.81 | |||||
ROCE % | 42.79 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 32.7 | |||||
Forward PE Ratio | 16.59 | |||||
PE Ratio without NRI | 26.02 | |||||
PEG Ratio | 0.85 | |||||
PS Ratio | 2.39 | |||||
PB Ratio | 4.61 | |||||
Price-to-Tangible-Book | 9.11 | |||||
EV-to-EBIT | 12.69 | |||||
EV-to-Forward-EBIT | 8.86 | |||||
EV-to-EBITDA | 11.59 | |||||
EV-to-Forward-EBITDA | 5.12 | |||||
EV-to-Revenue | 2.89 | |||||
EV-to-Forward-Revenue | 1.52 | |||||
EV-to-FCF | -14.92 | |||||
Price-to-GF-Value | 1.23 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.02 | |||||
Price-to-Graham-Number | 3.21 | |||||
| Price-to-Net-Current-Asset-Value | 31.31 | |||||
Earnings Yield (Greenblatt) % | 7.87 | |||||
FCF Yield % | -8.05 | |||||
Forward Rate of Return (Yacktman) % | 17.21 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil E£) | 4,297.175 | ||
| EPS (TTM) (E£) | 0.156 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 1.1 | ||
| 3-Year Sortino Ratio | 3.03 | ||
| Volatility % | 51.74 | ||
| 14-Day RSI | 50.04 | ||
| 14-Day ATR (E£) | 0.105539 | ||
| 20-Day SMA (E£) | 5.0595 | ||
| 12-1 Month Momentum % | 52.38 | ||
| 52-Week Range (E£) | 3.021992 - 5.38 | ||
| Shares Outstanding (Mil) | 2,000 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Stock Events
| Event | Date | Price (E£) | ||
|---|---|---|---|---|
| EGP 0.030000 Cash Dividend | 2026-06-02 | 5.15 (+1.78%) | ||
| 1.32363:1 Stock Split | 2025-12-03 | 3.15 (+1.21%) | ||
| EGP 0.080401 Cash Dividend | 2025-07-07 | 3.35 (+0.45%) | ||
| 1.52253:1 Stock Split | 2023-09-21 | 1.14 (+0.00%) | ||
| 1.30107:1 Stock Split | 2021-09-23 | 1.06 (+0.00%) |
Show
Entries
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Frequently Asked Questions
What is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents(CAI:RMDA)'s stock price today?
The current price of CAI:RMDA is E£5.10. The 52 week high of CAI:RMDA is E£5.38 and 52 week low is E£3.02.
When is next earnings date of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents(CAI:RMDA)?
The next earnings date of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents(CAI:RMDA) is .
Does Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents(CAI:RMDA) pay dividends? If so, how much?
The Dividend Yield %  of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents(CAI:RMDA) is 0.6% (As of Today), Highest Dividend Payout Ratio of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents(CAI:RMDA) was 0.47. The lowest was 0.04. And the median was 0.28. The  Forward Dividend Yield % of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents(CAI:RMDA) is 0.6%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers